The company will initiate a phase 2 trial to evaluate BIO 300 (oral, genistein antioxidant) to mitigate impaired pulmonary function in COVID-19 patients recently discharged from the hospital. COVID-19- and radiation-mediated lung damage share overlapping mechanisms of injury, and Humanetics already has BIO300 under study in the clinic to treat pneumonitis and pulmonary fibrosis in lung cancer patients receiving thoracic radiotherapy.